title: The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.
abstract: High-dose-rate (HDR) brachytherapy as monotherapy is a comparatively new brachytherapy procedure for prostate cancer. In addition to the intrinsic advantages of brachytherapy, including radiation dose concentration to the tumor and rapid dose fall-off at the surrounding normal tissue, HDR brachytherapy can yield a more homogeneous and conformal dose distribution through image-based decisions for source dwell positions and by optimization of individual source dwell times. Indication can be extended even to T3a/b or a part of T4 tumors because the applicators can be positioned at the extracapsular lesion, into the seminal vesicles, and/or into the bladder, without any risk of source migration or dropping out. Unlike external beam radiotherapy, with HDR brachytherapy inter-/intra-fraction organ motion is not problematic. However, HDR monotherapy requires patients to stay in bed for 1-4 days during hospitalization, even though the actual overall treatment time is short. Recent findings that the α/β value for prostate cancer is less than that for the surrounding late-responding normal tissue has made hypofractionation attractive, and HDR monotherapy can maximize this advantage of hypofractionation. Research on HDR monotherapy is accelerating, with a growing number of publications reporting excellent preliminary clinical results due to the high 'biologically effective dose (BED)' of >200 Gy. Moreover, the findings obtained for HDR monotherapy as an early model of extreme hypofractionation tend to be applied to other radiotherapy techniques such as stereotactic radiotherapy. All these developments point to the emerging role of HDR brachytherapy as monotherapy for prostate cancer.
authors.affiliation: Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Ken
authors.initials: K
authors.lastname: Yoshida
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Norio
authors.initials: N
authors.lastname: Nonomura
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D001918:Brachytherapy / Q000295:instrumentation* / Q000379:methods* / Q000639:trends; D019583:Dose Fractionation, Radiation; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D016896:Treatment Outcome
keywords: brachytherapy; high-dose-rate (HDR); hypofractionation; monotherapy; prostate cancer
references.citation: Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1474-82
references.pmid: 15964706
references.citation: Expert Rev Anticancer Ther. 2009 Jan;9(1):61-5
references.pmid: 19105707
references.citation: Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):6-13
references.pmid: 11777617
references.citation: Radiother Oncol. 2003 Sep;68(3):285-8
references.pmid: 13129636
references.citation: Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):213-20
references.pmid: 12694841
references.citation: Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):469-75
references.pmid: 20646858
references.citation: Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1013-5
references.pmid: 15519768
references.citation: Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):85-90
references.pmid: 20605353
references.citation: Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1588-97
references.pmid: 18374232
references.citation: Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):675-81
references.pmid: 11020563
references.citation: Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1889-96
references.pmid: 21550182
references.citation: Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1376-84
references.pmid: 21680108
references.citation: Brachytherapy. 2012 Mar-Apr;11(2):105-10
references.pmid: 21917528
references.citation: Brachytherapy. 2010 Jan-Mar;9(1):36-41
references.pmid: 19736046
references.citation: Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):441-6
references.pmid: 18249501
references.citation: Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1063-71
references.pmid: 15001246
references.citation: Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81-90
references.pmid: 11777625
references.citation: Cancer. 2012 Aug 1;118(15):3681-90
references.pmid: 22170628
references.citation: Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55
references.pmid: 17531401
references.citation: Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82
references.pmid: 21300474
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-24
references.pmid: 21324610
references.citation: Brachytherapy. 2012 Jan-Feb;11(1):20-32
references.pmid: 22265435
references.citation: Radiother Oncol. 2005 Feb;74(2):137-48
references.pmid: 15734201
references.citation: Brachytherapy. 2009 Jan-Mar;8(1):45-51
references.pmid: 19038584
references.citation: Am J Clin Oncol. 2010 Oct;33(5):481-8
references.pmid: 19952715
references.citation: J Clin Oncol. 2003 May 15;21(10):1904-11
references.pmid: 12743142
references.citation: Radiother Oncol. 2011 Feb;98(2):192-7
references.pmid: 21295878
references.citation: Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):525-33
references.pmid: 9635698
references.citation: Strahlenther Onkol. 2004 Apr;180(4):225-32
references.pmid: 15057433
references.citation: Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1205-11
references.pmid: 10725633
references.citation: Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):686-92
references.pmid: 22795805
references.citation: Int J Urol. 2013 Feb;20(2):185-92
references.pmid: 22905941
references.citation: Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):194-203
references.pmid: 12504054
references.citation: Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1289-91
references.pmid: 21740993
references.citation: Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31
references.pmid: 11429230
references.citation: Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1472-7
references.pmid: 17689026
references.citation: Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1286-92
references.pmid: 21310546
references.citation: Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9
references.pmid: 11163498
references.citation: J Urol. 2012 Jan;187(1):109-16
references.pmid: 22088340
references.citation: Radiother Oncol. 2009 Nov;93(2):253-8
references.pmid: 19854524
references.citation: Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):6-16
references.pmid: 21481721
references.citation: Eur J Cancer. 2012 Jul;48(11):1664-71
references.pmid: 22336663
references.citation: Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101
references.pmid: 10192361
references.citation: Br J Radiol. 1989 Aug;62(740):679-94
references.pmid: 2670032
references.citation: Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):600-5
references.pmid: 21377288
references.citation: Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):672-8
references.pmid: 22929859
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):927-32
references.pmid: 22197086
references.citation: Radiother Oncol. 2006 Jul;80(1):62-8
references.pmid: 16870289